Format

Send to

Choose Destination
J Heart Lung Transplant. 2015 Jan;34(1):113-21. doi: 10.1016/j.healun.2014.09.021. Epub 2014 Sep 28.

A whole blood-based perfusate provides superior preservation of myocardial function during ex vivo heart perfusion.

Author information

1
Cardiac Sciences Program, University of Manitoba; Institute of Cardiovascular Sciences, St. Boniface Hospital.
2
Institute of Cardiovascular Sciences, St. Boniface Hospital.
3
Cardiac Sciences Program, University of Manitoba.
4
National Research Council Institute for Biodiagnostics Departments of.
5
Pathology.
6
Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
7
Papworth Hospital, Cambridge, United Kingdom.
8
Cardiac Sciences Program, University of Manitoba; Institute of Cardiovascular Sciences, St. Boniface Hospital; Cardiac Surgery, Mazankowski Alberta Heart Institute; Alberta Transplant Institute, University of Alberta, Edmonton, Alberta, Canada. Electronic address: dhfreed@ualberta.ca.

Abstract

BACKGROUND:

Ex vivo heart perfusion (EVHP) provides the opportunity to resuscitate unused donor organs and facilitates assessments of myocardial function that are required to demonstrate organ viability before transplantation. We sought to evaluate the effect of different oxygen carriers on the preservation of myocardial function during EVHP.

METHODS:

Twenty-seven pig hearts were perfused ex vivo in a normothermic beating state for 6 hours and transitioned into working mode for assessments after 1 (T1), 3 (T3), and 5 (T5) hours. Hearts were allocated to 4 groups according to the perfusate composition. Red blood cell concentrate (RBC, n = 6), whole blood (RBC+Plasma, n = 6), an acellular hemoglobin-based oxygen carrier (HBOC, n = 8), or HBOC plus plasma (HBOC+Plasma, n = 7) were added to STEEN Solution (XVIVO Perfusion, Goteborg, Sweden) to achieve a perfusate hemoglobin concentration of 40 g/liter.

RESULTS:

The perfusate composition affected the preservation of systolic (T5 dP/dtmax: RBC+Plasma = 903 ± 99, RBC = 771 ± 77, HBOC+Plasma = 691 ± 82, HBOC = 563 ± 52 mm Hg/sec; p = 0.047) and diastolic (T5 dP/dtmin: RBC+Plasma = -574 ± 48, RBC = -492 ± 63, HBOC+Plasma = -326 ± 32, HBOC = -268 ± 22 mm Hg/sec; p < 0.001) function, and the development of myocardial edema (weight gain: RBC+Plasma = 6.6 ± 0.9, RBC = 6.6 ± 1.2, HBOC+Plasma = 9.8 ± 1.7, HBOC = 16.3 ± 1.9 g/hour; p < 0.001) during EVHP. RBC+Plasma hearts exhibited less histologic evidence of myocyte damage (injury score: RBC+Plasma = 0.0 ± 0.0, RBC = 0.8 ± 0.3, HBOC+Plasma = 2.6 ± 0.2, HBOC = 1.75 ± 0.4; p < 0.001) and less troponin-I release (troponin-I fold-change T1-T5: RBC+Plasma = 7.0 ± 1.7, RBC = 13.1 ± 1.6, HBOC+Plasma = 20.5 ± 1.1, HBOC = 16.7 ± 5.8; p < 0.001). Oxidative stress was minimized by the addition of plasma to RBC and HBOC hearts (oxidized phosphatidylcholine compound fold-change T1-T5: RBC+Plasma = 1.83 ± 0.20 vs RBC = 2.31 ± 0.20, p < 0.001; HBOC+Plasma = 1.23 ± 0.17 vs HBOC = 2.80 ± 0.28, p < 0.001).

CONCLUSIONS:

A whole blood-based perfusate (RBC+Plasma) minimizes injury and provides superior preservation of myocardial function during EVHP. The beneficial effect of plasma on the preservation of myocardial function requires further investigation.

KEYWORDS:

HBOC; ex vivo heart perfusion; ex vivo perfusate; hemoglobin-based oxygen carrier; myocardial energy metabolism; myocardial function; oxygen delivery

PMID:
25447577
DOI:
10.1016/j.healun.2014.09.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center